SPECIALTY GUIDELINE MANAGEMENT

DESFERAL (deferoxamine) deferoxamine mesylate (generic)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Chronic iron overload due to transfusion-dependent anemias

B. Compendial Uses

- 1. Aluminum toxicity in patients undergoing dialysis
- 2. Hereditary hemochromatosis

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: Chronic iron overload due to transfusion-dependent anemias:

- A. Initial requests: pretreatment serum ferritin level
- B. Continuation requests: current serum ferritin level

III. CRITERIA FOR INITIAL APPROVAL

A. Chronic Iron Overload due to Transfusion-Dependent Anemias

Authorization of 6 months may be granted for treatment of chronic iron overload due to transfusion-dependent anemias when the pretreatment serum ferritin level is consistently greater than 1000 mcg/L.

B. Aluminum toxicity in Members Undergoing Dialysis

Authorization of 6 months may be granted for treatment of aluminum toxicity in members undergoing dialysis.

C. Hereditary Hemochromatosis

Authorization of 6 months may be granted for treatment of hereditary hemochromatosis when phlebotomy is not an option (e.g., poor candidate due to underlying medical disorders) or the member had an unsatisfactory response to phlebotomy.

IV. CONTINUATION OF THERAPY

deferoxamine-Desferal 1620-A SGM P2021.docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III when the following criteria are met:

A. Chronic Iron Overload due to Transfusion-Dependent Anemias

Member is experiencing benefit from therapy as evidenced by a decrease in serum ferritin levels as compared to pretreatment baseline.

B. Aluminum toxicity in Members Undergoing Dialysis

Member is experiencing benefit from therapy as evidenced by any of the following:


- 1. Decreased serum aluminum concentrations
- 2. Symptomatic improvement (e.g., neurological symptom improvement, decreased bone pain)

C. Hereditary Hemochromatosis

Member is experiencing benefit from therapy as evidenced by a decrease in serum ferritin levels as compared to pretreatment baseline.

V. REFERENCES

- 1. Desferal [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2020.
- 2. Deferoxamine mesylate [package insert]. Lake Forest, IL: Hospira, Inc.; August 2020.
- 3. Micromedex Solutions [database online]. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: www.micromedexsolutions.com. Accessed October 7, 2020.
- 4. AHFS DI (Adult and Pediatric) [database online]. Lexi-Comp, Inc. Hudson, OH. Available at: http://online.lexi.com/lco/action/index/dataset/complete ashp [available with subscription]. Accessed October 7, 2020.
- Clinical Pharmacology [Internet]. Elsevier. Tampa (FL). Available from: http://www.clinicalpharmacology.com. October 7, 2020.
- 6. Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT) 3rd Edition [Internet]. Thalassaemia International Federation 2014;20:1-253.
- 7. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood 2012;120(18):3657-
- 8. Adams P, Barton J, et al. How I Treat Hemochromatosis. Blood 2010; (116): 317-325.



© 2021 CVS Caremark. All rights reserved.

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written